Biotech Company Reveals Major Data From Acute Myeloid Leukemia Study

Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024, the company presented interim results from its ongoing Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). The presentation took place at the 2024 European Hematology Association (EHA) Congress in Madrid, Spain. $Bio-Path Holdings(BPTH.US)$